Risk of Neuropsychiatric Diseases According to the Use of a Leukotriene Receptor Antagonist in Middle-Aged and Older Adults with Asthma: A Nationwide Population-Based Study Using Health Claims Data in Korea

Liu, 2015, The role of leukotrienes in allergic diseases, Allergol Int, 64, 17, 10.1016/j.alit.2014.09.001 Ogawa, 2006, The role of leukotrienes in airway inflammation, J Allergy Clin Immunol, 118, 789, 10.1016/j.jaci.2006.08.009 Duroudier, 2009, Leukotriene pathway genetics and pharmacogenetics in allergy, Allergy, 64, 823, 10.1111/j.1398-9995.2009.02015.x Law, 2018, Neuropsychiatric events associated with leukotriene-modifying agents: a systematic review, Drug Saf, 41, 253, 10.1007/s40264-017-0607-1 Benard, 2017, Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice, Eur Respir J, 50, 1700148, 10.1183/13993003.00148-2017 2020 Kim, 2020, Conducting and reporting a clinical research using Korean healthcare claims database, Korean J Fam Med, 41, 146, 10.4082/kjfm.20.0062 Seong, 2017, Cohort profile: the National Health Insurance Service–National Health Screening Cohort (NHIS-HEALS) in Korea, BMJ Open, 7, e016640, 10.1136/bmjopen-2017-016640 Torgersen, 2009, The nature (and nurture) of personality disorders, Scand J Psychol, 50, 624, 10.1111/j.1467-9450.2009.00788.x Shah, 2014, Suicide in centenarians: the international landscape, Int Psychogeriatr, 26, 1703, 10.1017/S1041610214001112 Bowden, 2018, Risk of suicide following an alcohol-related emergency hospital admission: an electronic cohort study of 2.8 million people, PLoS One, 13, e0194772, 10.1371/journal.pone.0194772 D'Hoore, 1993, Risk adjustment in outcome assessment: the Charlson Comorbidity index, Methods Inf Med, 32, 382, 10.1055/s-0038-1634956 Kim, 2014, Prevalence and trends of dementia in Korea: a systematic review and meta-analysis, J Korean Med Sci, 29, 903, 10.3346/jkms.2014.29.7.903 Woszczek, 2010, Concentration-dependent noncysteinyl leukotriene type 1 receptor–mediated inhibitory activity of leukotriene receptor antagonists, J Immunol, 184, 2219, 10.4049/jimmunol.0900071 Luginina, 2019, Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs, Sci Adv, 5, eaax2518, 10.1126/sciadv.aax2518 Shin, 2015, Leukotriene enhanced allergic lung inflammation through induction of chemokine production, Clin Exp Med, 15, 233, 10.1007/s10238-014-0292-7 Haarman, 2017, Adverse drug reactions of montelukast in children and adults, Pharmacol Res Perspect, 5, e00341, 10.1002/prp2.341 Glockler-Lauf, 2019, Montelukast and neuropsychiatric events in children with asthma: a nested case-control study, J Pediatr, 209, 176, 10.1016/j.jpeds.2019.02.009 Ghosh, 2016, Cysteinyl leukotrienes and their receptors: emerging therapeutic targets in central nervous system disorders, CNS Neurosci Ther, 22, 943, 10.1111/cns.12596 Gelosa, 2017, Cysteinyl leukotrienes as potential pharmacological targets for cerebral diseases, Mediators Inflamm, 2017, 3454212, 10.1155/2017/3454212 Eriksson, 2018, The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain, Cell Death Dis, 9, 775, 10.1038/s41419-018-0783-7 Tseng, 2020, In vitro cytotoxicity of montelukast in HAPI and SH-SY5Y cells, Chem Biol Interact, 326, 109134, 10.1016/j.cbi.2020.109134 Ducharme, 2017, Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice, Eur Respir J, 50, 1702135, 10.1183/13993003.02135-2017 Storms, 2007, Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction, Expert Opin Pharmacother, 8, 2173, 10.1517/14656566.8.13.2173 Lee, 2020, Montelukast use over the past 20 years: monitoring of its effects and safety issues, Clin Exp Pediatr, 63, 376, 10.3345/cep.2019.00325 2019 Sansing-Foster, 2021, Risk of psychiatric adverse events among montelukast users, J Allergy Clin Immunol Pract, 8, 385, 10.1016/j.jaip.2020.07.052 Jick, 2009, Rate of suicide in patients taking montelukast, Pharmacotherapy, 29, 165, 10.1592/phco.29.2.165 Schumock, 2012, Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study, J Allergy Clin Immunol, 130, 368, 10.1016/j.jaci.2012.04.035 Chen, 2014, Asthma and self-harm: a population-based cohort study in Taiwan, J Psychosom Res, 77, 462, 10.1016/j.jpsychores.2014.08.017 Ali, 2015, Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case-control study, Pharmacoepidemiol Drug Saf, 24, 435, 10.1002/pds.3758 Biswas, 2001, Pharmacosurveillance and safety of the leukotriene receptor antagonist (LTRA), montelukast, Clin Exp Allergy Rev, 1, 300, 10.1046/j.1472-9725.2001.t01-1-00016.x Twaites, 2007, Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England, Drug Saf, 30, 419, 10.2165/00002018-200730050-00005 Wallerstedt, 2009, Montelukast and psychiatric disorders in children, Pharmacoepidemiol Drug Saf, 18, 858, 10.1002/pds.1794 Bygdell, 2012, Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population, Pharmacoepidemiol Drug Saf, 21, 79, 10.1002/pds.2265 Cereza, 2012, Nightmares induced by montelukast in children and adults, Eur Respir J, 40, 1574, 10.1183/09031936.00092812 Schumock, 2012, The association between leukotriene-modifying agents and spontaneously reported suicide, Drug Inf J, 46, 99, 10.1177/0092861511427856 Marchand, 2013, Psychiatric disorders associated with montelukast: data from the National Pharmacovigilance Database [in French], Arch Pediatr, 20, 269, 10.1016/j.arcped.2012.12.006 Aagaard, 2014, Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011, Int J Clin Pharm, 36, 1222, 10.1007/s11096-014-0020-0 Lafay-Chebassier, 2015, Drug-induced depression: a case/non case study in the French Pharmacovigilance database, Therapie, 70, 425, 10.2515/therapie/2015026 Aldea Perona, 2016, Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase, Drug Saf, 39, 69, 10.1007/s40264-015-0360-2 Huang, 2020, Montelukast does not increase the risk of attention-deficit/hyperactivity disorder in pediatric asthma patients: A nationwide population-based matched cohort study, J Formos Med Assoc